We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Clear Labs

Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex diagnostics for clinical and a... read more Featured Products: More products

Download Mobile App





Groundbreaking Solution Enables Enhanced Screening and Genomic Surveillance of SARS-CoV-2 and its Mutations

By LabMedica International staff writers
Posted on 17 Sep 2021
The first-ever turn-key solution for whole genome sequencing (WGS) of COVID-19 is expected to help hospitals, reference labs, public health organizations and epidemiologists more easily identify and trace all strains of SARS-CoV-2.

Clear Labs (San Carlos, CA, USA), provider of the only fully-automated next-generation sequencing (NGS) platform for turnkey diagnostics, has launched Clear Dx WGS, the first automated WGS solution that determines the complete RNA sequence of the SARS-CoV-2 genome in less than 24-hours, a fraction of time, compared with traditional manual WGS workflows, requiring only minutes of hands-on time. More...
The Clear Dx platform is powered by NGS, robotics and cloud-based analytics. As a result, Clear Dx WGS can more easily determine the nature of virus transmission by differentiating virus strains (including flagging super-spreader events), and monitoring mutations, which can lead to variants.

By delivering rapid sequencing of the whole genome, the Clear Dx platform provides fully-automated library preparation and management, including cDNA synthesis, amplification of targets, indexing, and nucleic acid clean-up. It also provides simplified WGS workflow with ~30 minutes hands-on time (i.e. 1-2 human touch points vs. several dozen touch points with existing manual WGS workflows). Additionally, the platform offers faster results - from days to less than 24 hours; improved consistency in sample processing and accuracy of results; and lower labor costs and greater lab productivity.

“This is a pivotal time for our understanding and management of the ongoing COVID-19 pandemic, and better, more accurate intel is critical,” said Jeff Field, Chief Commercial Officer at Clear Labs. “Our platform can identify different subtypes of the SARS-CoV-2 virus based on its genomic fingerprint. We recognize that it’s no longer enough to confirm cases, it’s about understanding the mutations and evolution of the virus, so the virus can be traced and understood. Ultimately, this leads to timely decisions which can be made to keep people safe. With our unique approach that democratizes genomics applications, Clear Dx WGS can quickly identify new subtypes, mutations, and variants to gain real-time clarity into virus transmission, so it's actionable.”

“In addition to WGS, the platform also features the Clear Dx SARS-CoV-2 Diagnostic Assay (EUA approved) which allows labs to perform diagnostic screening and genomic surveillance simultaneously,” added Field. “For the same price of a traditional PCR screening test, our fully-automated targeted NGS assay delivers same-day results and a comprehensive look into the virus - by differentiating positives into genomic subtypes and flagging clinically-relevant lineages or mutations, such as B.1.1.7, B.1.351, L452R, and D614G. Given the evolution of SARS-CoV-2, it's imperative that the market starts to adopt and implement NGS-based testing solutions to ensure that new strains such as B.1.1.7 are not being missed by conventional testing methods.”




Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Collection and Transport System
PurSafe Plus®
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.